Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: Adam C. Derbyshire
Mike Freeman
Vice President and Director, Investor Relations and
Chief Financial Officer Corporate Communications
919 862-1000 919 862-1000
SALIX PHARMACEUTICALS PRESENTATION AT DEUTSCHE BANC ALEX. BROWN
CONFERENCE TO BE WEBCAST LIVE
RALEIGH, NC, May 7, 2001 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today
announced that Robert Ruscher, President and Chief Executive Officer, will
present to the investment community at Deutsche Banc Alex. Brown's 26/th/ Annual
Health Care Conference in Baltimore, MD at 2:00 p.m. EDT on Tuesday, May 8,
2001.
Interested parties can access a live audio webcast of the presentation at
http://www.db.com/conferences. A replay of the presentation will be available
- -----------------------------
by the end of the day, May 8, and will be archived for seven days.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops
and markets prescription pharmaceutical products for the treatment of
gastrointestinal diseases. Salix's strategy is to in-license proprietary
therapeutic drugs that have an existing database of positive, late-stage
clinical data; complete the development and regulatory submission of these
products; and market them through the Company's gastroenterology specialty sales
force. Salix's lead product is COLAZAL, an anti-inflammatory drug approved for
the treatment of mildly to moderately active ulcerative colitis. The Company
launched the product in the U.S. through its specialty sales force in January
2001. Salix's follow-on product candidate is rifaximin, currently in development
for the potential treatment of infections of the lower gastrointestinal tract.
The
Company currently intends to submit an NDA for rifaximin for the treatment of
infectious diarrhea to the U.S. FDA in late 2001. Salix trades on the Nasdaq
National Market under the ticker symbol "SLXP."
For more information please contact the Company at 919-862-1000 or visit our web
site at www.salixpharm.com.
------------------
Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include the risks of clinical
trials and regulatory review, market acceptance of our products, and the need
to acquire new products. The reader is referred to the documents that the
Company files from time to time with the Securities and Exchange Commission.